Cargando…
Cytarabine delivered by CD44 and bone targeting redox-sensitive liposomes for treatment of acute myelogenous leukemia
Acute myelogenous leukemia (AML) remains a serious fatal disease for the patients and effective treatment strategies are urgently needed. Based on the characteristics of the AML, we developed the CD44 and bone targeting liposomes delivery system decorated with the redox-cleavable polymer. First, ALN...
Autores principales: | Wu, Hao, Gao, Yuan, Ma, Jia, Hu, Maosong, Xia, Jing, Bao, Shuting, Liu, Yuxi, Feng, Kai |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9469920/ https://www.ncbi.nlm.nih.gov/pubmed/36110161 http://dx.doi.org/10.1093/rb/rbac058 |
Ejemplares similares
-
Behenoyl cytarabine-associated reversible encephalopathy in a patient with acute myelogenous leukemia.
por: Cho, S. G., et al.
Publicado: (1999) -
CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia
por: Lancet, Jeffrey E., et al.
Publicado: (2018) -
Treatment of lymphomatous and leukemic meningitis with liposomal encapsulated cytarabine
por: Kripp, Melanie, et al.
Publicado: (2008) -
Liposomal Cytarabine as Cancer Therapy: From Chemistry to Medicine
por: Salehi, Bahare, et al.
Publicado: (2019) -
Reformulating acute myeloid leukemia: liposomal cytarabine and daunorubicin (CPX-351) as an emerging therapy for secondary AML
por: Chen, Evan C, et al.
Publicado: (2018)